Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...
Barchart Research What to Expect from PROK Earnings PROK Generated May 15, 2026 Current Price $1.6600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Loss Narrative Continues,...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase...
Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...
Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...
Barchart Research What to Expect from PROK Earnings PROK Generated May 8, 2026 Current Price $1.8600 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 6.69% ProKidney's Earnings Call Will...
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned...
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of...